The state of Georgia currently has 19 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including Atlanta, Augusta, Decatur and Savannah.
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
Recruiting
This is a multi-center, randomized, double blind, adaptive, parallel-group, placebo controlled Phase 1b study to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics of RO7486967 in participants with idiopathic PD at the early stage of the disease (modified H&Y stage ≤2.5) who are either treatment-naïve or on stable treatment with symptomatic therapy (levodopa and/or pramipexole, ropinirole, rotigotine).
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
02/15/2024
Locations: NeuroStudies.net, LLC, Decatur, Georgia
Conditions: Parkinson Disease
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
Recruiting
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tas... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
02/09/2024
Locations: NeuroTrials Research Inc., Atlanta, Georgia
Conditions: Parkinson Disease, Tremor
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
Recruiting
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
02/08/2024
Locations: Pd0060 50578, Decatur, Georgia
Conditions: Parkinson Disease
Lu AF28996 in Participants With Parkinson's Disease (PD)
Recruiting
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
Gender:
All
Ages:
Between 45 years and 85 years
Trial Updated:
02/07/2024
Locations: Atlanta Center for Medical Research, Atlanta, Georgia
Conditions: Parkinson Disease
Early Parkinson's Disease Monotherapy With CVN424
Recruiting
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 compared to placebo in early, untreated Parkinson's Disease (PD) and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
01/26/2024
Locations: Augusta University, Augusta, Georgia
Conditions: Parkinson Disease
Partnered Dance Aerobic Exercise as a Neuroprotective, Motor and Cognitive Intervention in Parkinson's Disease
Recruiting
Parkinson's disease (PD) is a difficult to treat condition that impairs mobility and thinking. It is not fully treated by drugs and surgery. Two priority issues for most people with PD are "OFF-time" and Cognitive impairment. Even under best medical management, 74% of people with PD experience "OFF-time," which is when medications are just not working right. OFF-time severely impacts both quality of life and thinking. Cognitive problems are found even in newly diagnosed people with PD and are ve... Read More
Gender:
All
Ages:
Between 40 years and 89 years
Trial Updated:
01/24/2024
Locations: Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia
Conditions: Parkinson's Disease, Exercise Therapy, Cognition
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
Recruiting
Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.
Gender:
All
Ages:
Between 45 years and 75 years
Trial Updated:
01/23/2024
Locations: Emory University Hospital, Atlanta, Georgia +1 locations
Conditions: Parkinson Disease
Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
Recruiting
This study will be conducted with In-clinic visits and treatment at home for each patient with established Parkinson's disease (PD) experiencing daily OFF episodes.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
01/03/2024
Locations: CenExel iResearch Atlanta (Decatur), Decatur, Georgia
Conditions: Parkinson Disease
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
All
Ages:
30 years and above
Trial Updated:
12/13/2023
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Parkinson Disease
North American Prodromal Synucleinopathy Consortium Stage 2
Recruiting
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Emory University, Atlanta, Georgia
Conditions: REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
Recruiting
This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease. This 12 week study is designed to be 3:1 randomized across 3 doses of IkT-148009 or placebo. Each participant will self-administer one of 3 doses or placebo of IkT-148009 once daily (QD) with food for 12 weeks. F... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
11/17/2023
Locations: Neurology, Savannah, Georgia
Conditions: Parkinson Disease
Automated Imaging Differentiation of Parkinsonism
Recruiting
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
11/13/2023
Locations: Augusta University, Augusta, Georgia
Conditions: Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy